Evidence map›Paper›PMID 29351987›Full record

ArticleHaematologica2018

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

Ziduo Li, Xinsheng Ju, Kenneth Lee, Candice Clarke, Jennifer L Hsu, Edward Abadir, Christian E Bryant, Suzanne Pears, Neroli Sunderland, Scott Heffernan and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. CD83 in Hodgkin lymphoma.Haematologica · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

Ziduo LiDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Xinsheng JuDendritic Cell Research, ANZAC Research Institute, Sydney, Australia xinsheng.ju@sydney.edu.au.
Kenneth LeeSydney Medical School, University of Sydney, Australia.
Candice ClarkeDepartment of Anatomical Pathology, Concord Repatriation General Hospital, Sydney, Australia.
Jennifer L HsuDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Edward AbadirDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Christian E BryantDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Suzanne PearsAnimal Facility, Royal Prince Alfred Hospital, Sydney, Australia.
Neroli SunderlandAnimal Facility, Royal Prince Alfred Hospital, Sydney, Australia.
Scott HeffernanAnimal Facility, Royal Prince Alfred Hospital, Sydney, Australia.
Annemarie HennessyAnimal Facility, Royal Prince Alfred Hospital, Sydney, Australia.
Tsun-Ho LoDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Geoffrey A PieterszBurnet Institute, Melbourne, Australia.
Fiona KupresaninDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Phillip D FrommDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Pablo A SilveiraDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Con TsonisDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Wendy A CooperSydney Medical School, University of Sydney, Australia.
Ilona CunninghamDepartment of Haematology, Concord Repatriation General Hospital, Sydney, Australia.
Christina BrownSydney Medical School, University of Sydney, Australia.
Georgina J ClarkDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Derek N J HartDendritic Cell Research, ANZAC Research Institute, Sydney, Australia.
Anzac Research Institute · AUUniversity of Sydney · AURoyal Prince Alfred Hospital · AUConcord Repatriation General Hospital · AUBaker Heart and Diabetes Institute · AUWestern Sydney University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy and hematopoietic stem cell transplantation are effective treatments for most Hodgkin lymphoma patients, however there remains a need for better tumor-specific target therapy in Hodgkin lymphoma patients with refractory or relapsed disease. Herein, we demonstrate that membrane CD83 is a diagnostic and therapeutic target, highly expressed in Hodgkin lymphoma cell lines and Hodgkin and Reed-Sternberg cells in 29/35 (82.9%) Hodgkin lymphoma patient lymph node biopsies. CD83 from Hodgkin lymphoma tumor cells was able to trogocytose to surrounding T cells and, interestingly, the trogocytosing CD83

Indexed as

AdolescentAdultAgedAntibodies, MonoclonalAntigens, CDBiomarkers, TumorCD83 AntigenFemaleHodgkin DiseaseHumansImmunoglobulinsMaleMembrane GlycoproteinsMiddle AgedMolecular Targeted TherapySalvage TherapyAntibodies, MonoclonalAntigens, CDBiomarkers, TumorCD83 AntigenImmunoglobulinsMembrane Glycoproteins

Identifiers

PMID29351987
PMCPMC5865416
OpenAlexW2793535555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.